Cleviprex (clevidipine) is in a very cluster of medicine known as atomic number 20 channel blockers. It works byreposeful the muscles of your heart and blood vessels.
Cleviprex is employed to treat high force per unit area (hypertension) in those that cannot take drugs orally.
Cleviprex might also be used for functions ex-directory during this medication guide.
Submit your review
Get emergency medical help if you have any of these signs of an allergic reaction to Cleviprex: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Tell your caregiver at once if you have a serious side effect such as:
feeling like you might pass out;
rapid heart rate;
urinating less than usual or not at all;
weakness, confusion, increased thirst, loss of appetite, vomiting, pounding heartbeats or fluttering in your chest;
swelling, weight gain, feeling short of breath;
vomiting, diarrhea, stomach cramps, bloating, severe constipation;
chest pain or heavy feeling, pain spreading to the arm or shoulder, sweating, general ill feeling;
slow heart rate, weak pulse, fainting, slow breathing (breathing may stop); or
dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, uneven heartbeats, seizure).
Less serious Cleviprex side effects may include:
mild nausea; or
Recommended Dosing Cleviprex is intended for intravenous use. Titrate drug to achieve the desired blood pressure reduction. Individualize dosage depending on the blood pressure to be obtained and the response of the patient. Initial dose: Initiate the intravenous infusion of Cleviprex at 1-2 mg/hour. Dose titration: The dose may be doubled at short (90 second) intervals initially. As the blood pressure approaches goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. An approximately 1-2 mg/hour increase will generally produce an additional 2-4 mmHg decrease in systolic pressure. Maintenance dose: The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Patients with severe hypertension may require doses up to 32 mg/hour, but there is limited experience at this dose rate. Maximum dose: Most patients were treated with maximum doses of 16 mg/hour or less.There is limited short-term experience with doses up to 32 mg/hour. Because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Cleviprex infusion is recommended per 24 hour period. In clinical trials, 55 hypertensive patients were treated with >500mL of Cleviprex infusion per 24 hour period. There is little experience with infusion durations beyond 72 hours at any dose. Transition to an oral antihypertensive agent: Discontinue Cleviprex or titrate downward while appropriate oral therapy is established. When an oral antihypertensive agent is being instituted, consider the lag time of onset of the oral agent’s effect. Continue blood pressure monitoring until desired effect is achieved. Special populations: Special populations were not specifically studied. In clinical trials, 78 patients with abnormal hepatic function (one or more of the following: elevated serum bilirubin, AST/SGOT, ALT/SGPT) and 121 patients with moderate to severe renal impairment were treated with Cleviprex. An initial Cleviprex infusion rate of 1-2 mg/hour is appropriate in these patients.